TGFB1 and prostate carcinoma: Re-introduction of miR-539 into prostate cancer cells inhibits expression of DLX1, leading to attenuation of TGF-β signaling, inhibition of proliferation, migration, and invasion, as well as growth of prostate cancer xenografts in mice [320].